机构：[1]National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China首都医科大学宣武医院[2]The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China[3]Townsend Family Laboratories, Department of Psychiatry, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada[4]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang, China
Amyloid & beta; protein (A & beta;) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer's pathogenesis and progression. A & beta; has been the prime target for the development of AD therapy. However, the repeated failures of A & beta;-targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of Alzheimer's drug has followed the correct course. However, the recent successes of A & beta; targeted trials have assuaged those doubts. In this review, we discussed the evolution of the amyloid cascade hypothesis over the last 30 years and summarized its application in Alzheimer's diagnosis and modification. In particular, we extensively discussed the pitfalls, promises and important unanswered questions regarding the current anti-A & beta; therapy, as well as strategies for further study and development of more feasible A & beta;-targeted approaches in the optimization of AD prevention and treatment.
基金：
National Natural Science Foundation of China [82201576, 82293642, QML20210804, 2021-8]; Beijing Hospitals Authority Youth Programme [82150710557]; Beijng Medical Research [82230043]
第一作者机构：[1]National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]National Clinical Research Center for Geriatric Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China[2]The Second Affiliated Hospital and Yuying Children’s Hospital, Institute of Aging, Key Laboratory of Alzheimer’s Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China[3]Townsend Family Laboratories, Department of Psychiatry, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada[4]Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health), Wenzhou, Zhejiang, China
推荐引用方式(GB/T 7714)：
Zhang Yun,Chen Huaqiu,Li Ran,et al.Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future[J].SIGNAL TRANSDUCTION AND TARGETED THERAPY.2023,8(1):doi:10.1038/s41392-023-01484-7.
APA：
Zhang, Yun,Chen, Huaqiu,Li, Ran,Sterling, Keenan&Song, Weihong.(2023).Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.SIGNAL TRANSDUCTION AND TARGETED THERAPY,8,(1)
MLA：
Zhang, Yun,et al."Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future".SIGNAL TRANSDUCTION AND TARGETED THERAPY 8..1(2023)
医学